Abstract
Platelets are key players in arterial thrombosis, and oral antiplatelet therapy is a cornerstone in the treatment and prevention of cardiovascular events. However, although currently approved antiplatelet drugs have proved successful in reducing cardiovascular events, platelet-dependent thrombosis remains an important cause of morbidity and mortality in patients with coronary artery disease. It is well-known that patients with diabetes mellitus (DM) have an increased risk of cardiovascular events and, therefore, understanding the mechanism of action and safety profile of antiplatelet drugs in this high-risk population is of particular interest. There is considerable inter-individual variation in the efficacy of established antiplatelet drugs, and high on-treatment platelet reactivity is associated with an increased risk of cardiovascular events, thus prompting the search for novel drugs against platelet-dependent thrombosis. New antiplatelet treatment strategies include drugs with more efficient and reversible platelet inhibition. This review discusses selective inhibitors of the platelet cyclooxygenase enzyme, thienopyridine and non-thienopyridine inhibitors of the platelet adenosine diphosphate receptor, phosphodiesterase inhibitors, and protease-activated receptor antagonists. An overview of currently available antiplatelet drugs is provided, focusing on benefits and limitations in patients with DM. Furthermore, the rationale for new oral antiplatelet drugs under development is discussed with particular focus on the potential role of these drugs to improve cardiovascular outcomes in patients with DM.
Keywords: Aspirin, coronary artery disease, diabetes mellitus, platelet aggregation inhibitors, prasugrel, platelets, ticagrelor, cyclooxygenase, thrombosis
Current Vascular Pharmacology
Title:Antiplatelet Therapy in Patients with Diabetes Mellitus
Volume: 10 Issue: 4
Author(s): Erik L. Grove and Soren Gregersen
Affiliation:
Keywords: Aspirin, coronary artery disease, diabetes mellitus, platelet aggregation inhibitors, prasugrel, platelets, ticagrelor, cyclooxygenase, thrombosis
Abstract: Platelets are key players in arterial thrombosis, and oral antiplatelet therapy is a cornerstone in the treatment and prevention of cardiovascular events. However, although currently approved antiplatelet drugs have proved successful in reducing cardiovascular events, platelet-dependent thrombosis remains an important cause of morbidity and mortality in patients with coronary artery disease. It is well-known that patients with diabetes mellitus (DM) have an increased risk of cardiovascular events and, therefore, understanding the mechanism of action and safety profile of antiplatelet drugs in this high-risk population is of particular interest. There is considerable inter-individual variation in the efficacy of established antiplatelet drugs, and high on-treatment platelet reactivity is associated with an increased risk of cardiovascular events, thus prompting the search for novel drugs against platelet-dependent thrombosis. New antiplatelet treatment strategies include drugs with more efficient and reversible platelet inhibition. This review discusses selective inhibitors of the platelet cyclooxygenase enzyme, thienopyridine and non-thienopyridine inhibitors of the platelet adenosine diphosphate receptor, phosphodiesterase inhibitors, and protease-activated receptor antagonists. An overview of currently available antiplatelet drugs is provided, focusing on benefits and limitations in patients with DM. Furthermore, the rationale for new oral antiplatelet drugs under development is discussed with particular focus on the potential role of these drugs to improve cardiovascular outcomes in patients with DM.
Export Options
About this article
Cite this article as:
L. Grove Erik and Gregersen Soren, Antiplatelet Therapy in Patients with Diabetes Mellitus, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812818
DOI https://dx.doi.org/10.2174/157016112800812818 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Integrated Acquisition of Analytical and Biopharmaceutical Screening Data for beta-Adrenergic-Drugs Employing Diversified Macrocycle Supported Potentiometric Detection in HPLC Systems
Current Medicinal Chemistry Can Statins Prevent Progression of Degenerated Aortic Valve Stenosis?
Vascular Disease Prevention (Discontinued) Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Linkage of CNS and Immunology with Psychology: Searching for New Pharmacological Targets)
CNS & Neurological Disorders - Drug Targets Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Pharmacological Inhibitors of Cysteinyl Leukotrienes Biosynthesis: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mortality According to a Prior Assessment of Biological Age
Current Aging Science The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Editorial [Hot Topic: Therapeutic Potential of Peptide Motifs - Part I (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Substance P in Rheumatic Diseases
Current Rheumatology Reviews Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design The Effect of Lead Exposure on Selected Blood Inflammatory Biomarkers in Guinea pigs
Cardiovascular & Hematological Disorders-Drug Targets Appropriate Anti-Thrombotic/Anti-Thrombin Therapy for Thrombotic Lesions
Current Cardiology Reviews Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions
Cardiovascular & Hematological Disorders-Drug Targets Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design The Experience of Depression Relapse among Adult Thai Patients with Depressive Disorder: A Qualitative Study
Current Psychiatry Research and Reviews Progressive Brain Damage and Alterations in Dendritic Arborization after Collagenase-Induced Intracerebral Hemorrhage in Rats
Current Neurovascular Research